GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Stopped early · Phase 1/Phase 2
Conditions studied: Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma, Gastric Cancer, Pancreatic Cancer, Urothelial Cancer
In brief
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
Key facts
- Study ID
- NCT03576131
- Run by
- Genmab
- People needed
- 48
- Starts
- 2018-04-30
- Expected to finish
- 2021-10-12
- Last updated by the study team
- 2023-08-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yale University — New Haven, Connecticut, United States
- UT M.D Anderson Cancer Center — Houston, Texas, United States
- Hospital Univeritario Vall d'Hebron — Barcelona, Spain
- START Madrid CIOCC — Madrid, Spain
- The Newcastle upon Tyne Hospitals NHS Foundation Trust — Newcastle, United Kingdom
- The Royal Mardsen NHS Foundation Trust — Sutton, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.